ATLANTA, GA--(MARKET WIRE)--Jul 14, 2008 -- Medspas of America Inc. (Other OTC:MEDP.PK - News), www.medspasofamerica.com. Two important clinical tests and nine additional clinical observations have been completed on Penzyme, leading to extremely favorable results and excellent news for Medspas. Penzim is the active and main ingredient in its Natural Renu anti-aging cream and gel.

Penzyme is truly an amazing product which utilizes purified enzymes that have a deep-healing effect on the body when applied. The versatility for uses of Penzyme provides Medspas with a giant global platform to market and distribute Natural Renu. Penzyme was found to accelerate the healing time for inflammation and pain for osteoarthritis, tendonitis, tendosynovitis, fibromyalgia, muscle aches, trigger points, rheumatoid arthritis, lymphagitis, varicose veins, phlebitis and also helps to reduce pain of UV Radiation burns and wound-healing of pressure sores.

Cosmetically, Penzyme has been proven to provide relief of psoriasis, acne, boils, pimples, eczema and dermatitis, including nourishing, moisturizing, smoothing and rejuvenating the skin. "We believe we've stumbled onto a miracle cream and are extremely confident in the worldwide growth of Penzyme and feel fortunate that it collides directly with Medspa's success," stated CEO Paul Smith.

The beneficial properties of Penzyme have also been confirmed in laboratory research, partner funded clinical studies, and direct feedback from consumers. Clinical studies and observations of over 400 participants have been completed for the use of Penzyme in medical and cosmetic applications, which lends a great deal of credibility to its authenticity. "We are on a mission to get our Natural Renu product into every medicine cabinet across the globe," stated CEO Paul Smith.

Zymetech owns the worldwide patents for an active ingredient called Penzyme, which is sold under the trademark of Penzim, and is derived from enzymes produced by fish, particularly cod in the North Atlantic. The Company has signed a supply licensing agreement with Zymetech, Inc., www.zymetech.com, for the use of Penzim in its anti-aging product lines.

About Natural Renu

The company has established a new division to penetrate the $5.4 billion cosmeceutical industry under the brand name Natural Renu. The company's new initiative is a line of cosmeceutical products focusing on the anti-aging and skin healthcare markets. The company sales efforts are focused primarily through two marketing channels. The first and primary sales channel is Internet Retailing. The second target audience is to exclusive Plastic Surgeons and Dermatology practices, Day spas, Resorts and Medspas around the world.

SAFE HARBOR STATEMENT: Except for historical information contained herein, the statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the operations of a company.

     Investor Contact Information:
      
     Paul Smith
     Investor Relations
     1-866-595-1081